methyl 6-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate | 65844-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 6-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
• CAS: 65844-44-2
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: VHCLBOVLIDHZER-UHFFFAOYSA-N

物化性质

• 熔点：
  90-91 °C
• 沸点：
  344.2±42.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 6-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate 在 咪唑 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 正丁基锂 、 硼烷四氢呋喃络合物 、 四丁基氟化铵 、 戴斯-马丁氧化剂 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.75h， 生成 methyl 6-(2-(6-(benzyloxy)-1,2,3,4-tetrahydronaphthalene-2-carbonyl)oxazol-5-yl)picolinate
  参考文献：
  名称：

  Reversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting Analgesics

  摘要：

  A series of alpha-ketooxazoles containing conformational constraints in the C2 acyl side chain of 2 (OL-135) were examined as inhibitors of fatty acid amide hydrolase (FAAH). Only one of the two possible enantiomers displayed potent FAAH inhibition (S vs R enantiomer), and their potency is comparable or improved relative to 2, indicating that the conformational restriction in the C2 acyl side chain is achievable. A cocrystal X-ray structure of the alpha-ketoheterocycle 12 bound to a humanized variant of rat FAAH revealed its binding details, confirmed that the (S)-enantiomer is the bound active inhibitor, shed light on the origin of the enantiomeric selectivity, and confirmed that the catalytic Ser241 is covalently bound to the electrophilic carbonyl as a deprotonated hemiketal. Preliminary in vivo characterization of the inhibitors 12 and 14 is reported demonstrating that they raise brain anandamide levels following either intraperitoneal (ip) or oral (po) administration indicative of effective in vivo FAAH inhibition. Significantly, the oral administration of 12 caused dramatic accumulation of anandamide in the brain, with peak levels achieved between 1.5 and 3 h, and these elevations were maintained over 9 h. Additional studies of these two representative members of the series (12 and 14) in models of thermal hyperalgesia and neuropathic pain are reported, including the demonstration that 12 administered orally significantly attenuated mechanical (> 6 h) and cold (> 9 h) allodynia for sustained periods consistent with its long-acting effects in raising the endogenous concentration of anandamide.

  DOI：

  10.1021/jm101597x
• 作为产物：
  描述：

  methyl 6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate 在 高氯酸 、 palladium 10% on activated carbon 硫酸 、 氢溴酸 、 氢气 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 19.0h， 生成 methyl 6-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
  参考文献：
  名称：

  [EN] ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING
  [FR] ALPHA-CÉTOHÉTÉROCYCLES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  抑制脂肪酸酰胺水解酶的有效化合物已被披露，该酶负责代谢内源大麻素如阿南胺。这些化合物可用作镇痛化合物和诱导睡眠的化合物，可经口服给药，并具有相对较长的作用持续时间。还提供了这些化合物的制备方法。这些化合物是杂环酮的构象约束类似物，如噁唑基酮。

  公开号：

  WO2012106569A1

文献信息

• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Calderwood Emily F.

  公开号：US20120015942A1

  公开（公告）日：2012-01-19

  This invention provides compounds of formula (I): wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式（I）的化合物： 其中R1a、R1b、R1c、R2a、R2b、R2c和R2d的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• Anionic [4+2] cycloaddition strategy in the regiospecific synthesis of carbazoles: formal synthesis of ellipticine and murrayaquinone A
  作者：Dipakranjan Mal、Bidyut Kumar Senapati、Pallab Pahari

  DOI：10.1016/j.tet.2007.02.060

  日期：2007.4

  Anionic [4+2] cycloaddition of furoindolones (e.g., 7 and 10) has been developed as an effective means to the synthesis of carbazoles. This reaction has been shown to be feasible with a wide variety of Michael acceptors to give carbazoles and fused carbazoles in good yields. The scope and limitations of the reaction have been briefly studied. The nature of N-protection of the furoindolones (cf. 7)

  呋喃吲哚酮（例如7和10）的阴离子[4 + 2]环加成已被开发为咔唑合成的有效手段。已经表明该反应对于多种迈克尔受体是可行的，以高收率得到咔唑和稠合咔唑。已经简要研究了反应的范围和局限性。呋喃吲哚酮的N-保护性质（参见7）在环切成功中起着重要作用。
• [EN] ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING<br/>[FR] ALPHA-CÉTOHÉTÉROCYCLES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：BOGER DALE L

  公开号：WO2012106569A1

  公开（公告）日：2012-08-09

  Compounds are disclosed that are effective in inhibition of fatty acid amide hydrolase, an enzyme responsible for catabolism of endogenous cannabinoids such as anandamide. The compounds are useful as analgesic compounds and as sleep-inducing compounds, that can be orally administered, and that can have a relatively long duration of effect. Methods of preparation of the compounds are also provided. The compounds are conformationally constrained analogs of heterocyclylketones such as oxazolylketones.

  抑制脂肪酸酰胺水解酶的有效化合物已被披露，该酶负责代谢内源大麻素如阿南胺。这些化合物可用作镇痛化合物和诱导睡眠的化合物，可经口服给药，并具有相对较长的作用持续时间。还提供了这些化合物的制备方法。这些化合物是杂环酮的构象约束类似物，如噁唑基酮。
• [EN] S1P MODULATING AGENTS<br/>[FR] AGENTS MODULANT S1P
  申请人：BIOGEN IDEC INC

  公开号：WO2012109108A1

  公开（公告）日：2012-08-16

  Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

  化合物的分子式（I）或（II）可以调节SIP受体的活性。
• Total synthesis of BE-23254, a chlorinated angucycline antibiotic
  作者：Satyajit Dey、Dipakranjan Mal

  DOI：10.1016/j.tetlet.2005.06.062

  日期：2005.8

  The first synthesis of BE-23254, an unusual angucycline antibiotic, is reported. It involves regioselective condensation of naphthalenone 4 and chlorine-containing isobenzofuranone 16 as the key step.

  据报道，BE-23254是一种罕见的安古环素抗生素的首次合成。这是关键步骤，包括萘酮4和含氯异苯并呋喃酮16的区域选择性缩合。